Cambridge Cognition joining the UCSF Brain Health Registry as a cognitive assessment partner

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it will be joining the University of California, San Francisco (UCSF) Brain Health Registry as a cognitive assessment partner. The Brain Health Registry is an online platform designed to speed up the discovery of treatments for Alzheimer’s disease, Parkinson’s disease, depression, post-traumatic stress disorder, and other brain disorders.

One of the key barriers facing treatment development for neurological and psychiatric conditions is difficulty recruiting the right patients into clinical trials and identifying these individuals at the very early stages of disease progression. In efforts to address this issue researchers at UCSF established the Brain Health Registry: an online enrolment platform for adults who are interested in participating in brain research.

Adults aged 18+ years who are interested in participating in research studies can enrol in the Brain Health Registry through the website: https://my.brainhealthregistry.org/BHR/register. This secure, online platform is then used to deliver baseline questions on health, lifestyle and medical history. To build a full and sustained picture of function over an individual’s lifespan, participants are also asked to complete web-based questionnaires and cognitive assessments every 6 months: including the CANTABTM Paired Associates Learning task.

By regularly assessing healthy adults the Brain Health Registry is building a unique and important resource on functional change over time. This data will be used to identify potential candidates for clinical trials and establish novel biomarkers to detect early stages of brain disorders. This could be beneficial for Cambridge Cognition in providing more real-world data on the use of the assessment and potentially a cohort of patients already assessed with a CANTAB™ test that could be used for a clinical trial.

For further information on the Brain Health Registry visit https://www.brainhealthregistry.org/

Prof Michael Weiner, Lead Scientific Investigator at the Brain Health Registry, said:

“Accurate cognitive assessment is essential for the online Brain Health Registry to achieve its intended purpose: speeding up the discovery of effective treatments for brain disorders. Cambridge Cognition is joining us as a cognitive assessment partner helping us to speed up the discovery of effective treatments for brain disorders with their validated computerized cognitive assessments.”  

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

“One of the key challenges facing drug development is identifying which patients are most likely to benefit from a therapeutic intervention. The Brain Health Registry set up a web-based solution to tackle this issue: an online platform to longitudinally monitor adults who are interested in participating in research. The goal of our partnership is to assist the Brain Health Registry in bringing effective treatments for brain disorders by using our cognitive assessments.” 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition forms new Scientific Advisory Board

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, is pleased to announce the formation of a Scientific Advisory Board. This expert board will provide scientific guidance and valuable market insights, primarily focusing

Cambridge Cognition Holdings

Cambridge Cognition Holdings Changes its Auditor to Crowe UK LL

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Board has approved the appointment of Crowe UK LLP as the Group’s new external auditor following a competitive

Cambridge Cognition Holdings

Cambridge Cognition strengthens balance sheet with £3 million loan

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Company has obtained a £3.0 million loan from Claret European Specialty Lending Company III, S.à r.l.  Claret specialises in

Cambridge Cognition Holdings

Cambridge Cognition Holdings Revision to Explanatory Note

Cambridge Cognition (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the explanatory note to Resolution 7 in the Notice of the Annual General Meeting (“AGM”) to be held on 28 June 2023

Cambridge Cognition Holdings

Cambridge Cognition publishes Annual Report and Accounts

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has confirmed that the Annual Report and Accounts for the year ended 31 December 2022 and the Notice of the Annual General

Cambridge Cognition Holdings

Cambridge Cognition growth strategy clearly paying off (VIDEO)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk Interviews to discuss prelim results for the year ended 31 December 2022. In this interview Matthew talks us through the result highlights, explains how the the acquisitions